A Phase II Study of Combination Chemotherapy with and without Low-Dose Whole-Brain Radiation for Primary Central Nervous System Lymphoma

Protocol
11-125
Full Title
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low Dose Whole-Brain Radiotherapy from Primary Central Nervous System Lymphoma(RTOG 1114)
Phase
II
Purpose

The anticancer drugs rituximab, methotrexate, procarbazine, vincristine, and cytarabine are used in combination to treat primary central nervous system (CNS) lymphoma. In this study, investigators want to see if adding low-dose radiation therapy to this combination chemotherapy is more effective than combination chemotherapy alone for treating patients with primary CNS lymphoma. A previous study of this new treatment regimen produced promising results.

Patients will be randomly assigned to receive the chemotherapy combination with or without low-dose whole-brain radiation therapy.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have B-cell non-Hodgkin lymphoma involving the brain.
  • Patients may not have had prior chemotherapy or cranial radiation therapy for CNS lymphoma.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Antonio Omuro at 212-639-7523.

Disease(s)
Lymphoma
Lymphoma: Non-Hodgkin's Lymphoma
Pediatric Brain Tumors: CNS Cancer

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »